Use the search parameters below to filter talks:

Calendar
Calendar

2010 - TTS International Congress (Vancouver)

Clinical and Ethical Aspects of Living Donor Transplantation
16 August 2010  /  12:14 - 13:14

Is Living Donor Outcome Effected By Leaving Behind a Kidney With Multiple Arteries?

Presenter: Michael Rizzari, Minneapolis, United States

- Is Living Donor Outcome Effected By Leaving Behind a Kidney With Multiple Arteries?

Presenter: Michael Rizzari, Minneapolis, United States

Racial Disparities in Living Donor Rates: What Predicts the Likelihood of Receiving a Donor?

Presenter: Keren Ladin, Boston, United States

- Racial Disparities in Living Donor Rates: What Predicts the Likelihood of Receiving a Donor?

Presenter: Keren Ladin, Boston, United States

Long-term outcomes of living kidney donors – a single centre experience of 29 years

Presenter: kwok hong chu, hong kong, People's Republic of China

- Long-term outcomes of living kidney donors – a single centre experience of 29 years

Presenter: kwok hong chu, hong kong, People's Republic of China

Increasing kidney function in living kidney donors proceeds for a long time after nephrectomy

Presenter: John Söfteland, Göteborg, Sweden

- Increasing kidney function in living kidney donors proceeds for a long time after nephrectomy

Presenter: John Söfteland, Göteborg, Sweden

Age does not affect survival of kidneys from elderly living donors

Presenter: Mirjam Laging, Rotterdam, Netherlands

- Age does not affect survival of kidneys from elderly living donors

Presenter: Mirjam Laging, Rotterdam, Netherlands

Outcomes for donors and recipients following kidney donation from living donors, 65 years and older.

Presenter: Belinda Bennett, Parkville, Australia

- Outcomes for donors and recipients following kidney donation from living donors, 65 years and older.

Presenter: Belinda Bennett, Parkville, Australia

100 Kidney Transplants Performed Via Kidney Paired Donation at the Johns Hopkins Hospital

Presenter: Bonnie Lonze, Baltimore, United States

- 100 Kidney Transplants Performed Via Kidney Paired Donation at the Johns Hopkins Hospital

Presenter: Bonnie Lonze, Baltimore, United States

Living Kidney Donor Relationships in Caucasian and African-American Populations and Implications For Targeted Donor Education Programs

Presenter: Matthew Cooper, Baltimore, United States

- Living Kidney Donor Relationships in Caucasian and African-American Populations and Implications For Targeted Donor Education Programs

Presenter: Matthew Cooper, Baltimore, United States

Seven Non-simultaneous Extended Altruistic Donor (NEAD) Chains

Presenter: Michael Rees, TOLEDO, United States

- Seven Non-simultaneous Extended Altruistic Donor (NEAD) Chains

Presenter: Michael Rees, TOLEDO, United States

Induction Immunosuppression
16 August 2010  /  12:14 - 13:14

Low Dose Rabbit Anti-Thymocyte Globulin Induction Therapy Results in Prolonged Selective CD4 T Cell Depletion Irrespective of Maintenance Immunosuppression

Presenter: Oleh Pankewycz, BUFFALO, United States

- Low Dose Rabbit Anti-Thymocyte Globulin Induction Therapy Results in Prolonged Selective CD4 T Cell Depletion Irrespective of Maintenance Immunosuppression

Presenter: Oleh Pankewycz, BUFFALO, United States

Low dose rabbit anti-thymocyte globulin induction in low risk renal transplant recipients: 8 years follow up.

Presenter: Mark Reza Laftavi, Buffalo, United States

- Low dose rabbit anti-thymocyte globulin induction in low risk renal transplant recipients: 8 years follow up.

Presenter: Mark Reza Laftavi, Buffalo, United States

Safety of rituximab as induction therapy in renal transplantation; results of an interim analysis

Presenter: M.W.F. van den Hoogen, Nijmegen, Netherlands

- Safety of rituximab as induction therapy in renal transplantation; results of an interim analysis

Presenter: M.W.F. van den Hoogen, Nijmegen, Netherlands

IL2 Blocker Induction in Living Related Renal Transplantation

Presenter: Gopal Basu, Vellore, India

- IL2 Blocker Induction in Living Related Renal Transplantation

Presenter: Gopal Basu, Vellore, India

Low dose ATG induction for older kidney transplant recipients (old for old); single centre experience over 4 years.

Presenter: Martin Nitschke, Lübeck, Germany

- Low dose ATG induction for older kidney transplant recipients (old for old); single centre experience over 4 years.

Presenter: Martin Nitschke, Lübeck, Germany

Basiliximab Induction versus Alemtuzumab Induction with Steroid Free Maintenance in Kidney Transplantation: Two-Year Outcomes

Presenter: Kannan Samy, Toledo, United States

- Basiliximab Induction versus Alemtuzumab Induction with Steroid Free Maintenance in Kidney Transplantation: Two-Year Outcomes

Presenter: Kannan Samy, Toledo, United States

Interleukin-2 Receptor Antagonist Induction Therapy Leads To Increased Tacrolimus Levels After Kidney Transplantation

Presenter: Sonia Lin, Kingston, United States

- Interleukin-2 Receptor Antagonist Induction Therapy Leads To Increased Tacrolimus Levels After Kidney Transplantation

Presenter: Sonia Lin, Kingston, United States

Alemtuzumab (Campath-1H) induction and prednisone – free maintenance immunotherapy in kidney transplant Hispanic patients

Presenter: Yenny Baez, Bogota, Colombia

- Alemtuzumab (Campath-1H) induction and prednisone – free maintenance immunotherapy in kidney transplant Hispanic patients

Presenter: Yenny Baez, Bogota, Colombia

Effect of Induction Therapy on Acute Rejection risk and Severity, Infection and Malignancy-related mortality in Renal Transplant recipients

Presenter: Rebecca Croke, Perth, Australia

- Effect of Induction Therapy on Acute Rejection risk and Severity, Infection and Malignancy-related mortality in Renal Transplant recipients

Presenter: Rebecca Croke, Perth, Australia

Relationship Between Rejection and Infection after T-Cell Depleting Induction Therapy

Presenter: Alan Farney, Winston-Salem, United States

- Relationship Between Rejection and Infection after T-Cell Depleting Induction Therapy

Presenter: Alan Farney, Winston-Salem, United States

Alemtuzumab Induction and Tacrolimus Maintenance Immunosuppression with and without Mycophenolic Acid in Kidney Transplantation

Presenter: Kannan Samy, Toledo, United States

- Alemtuzumab Induction and Tacrolimus Maintenance Immunosuppression with and without Mycophenolic Acid in Kidney Transplantation

Presenter: Kannan Samy, Toledo, United States

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi